News

Tailored Rituxan Regimen for ANCA Vasculitis Patients as Effective, Possibly Safer than Fixed-schedule Treatment, Expert Says

An individually tailored treatment with Rituxan (rituximab) is as effective as the standard fixed-schedule regimen in preventing relapses over 28 months in ANCA-associated vasculitis (AAV) patients in remission. The data also indicated that the less frequent infusions in the tailored approach may improve safety, according to a…

Minimal Glucocorticoid Regimen Shows Similar Efficacy, Fewer Adverse Events than Standard Treatments, Study Reports

Patients with ANCA-associated vasculitis (AAV) who receive a minimal glucocorticoid treatment along with Rituxan (rituximab) and cyclophosphamide show similar improvement as those given standard glucocorticoid regimens, but have lower glucocorticoid-associated adverse events, a study shows. The study, “A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis,” was published…

Atypical ANCAs Do Not Contribute to Vessel Inflammation in Patients with Eye Disease, Study Suggests

The presence of atypical ANCA antibodies in people with underlying eye inflammatory disease is not linked to severe vessel inflammation or worse outcomes, a small study reports. The study, “Atypical Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Ocular Inflammatory Diseases,” was published in the journal Ocular Immunology and Inflammation. ANCA-associated…